Loading...

HighTide Therapeutics Inc

2511.HK•HKSE
Healthcare
Biotechnology
HK$3.52
HK$-0.27(-7.12%)

HighTide Therapeutics Inc (2511.HK) Stock Overview

Explore HighTide Therapeutics Inc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.5/100

Key Financials

Market Cap2B
P/E Ratio-3803.26
EPS (TTM)$-0.92
ROE-0.00%
Fundamental Analysis

AI Price Forecasts

1 Week$2.22
1 Month$-1.54
3 Months$0.00
1 Year Target$0.73

2511.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of HighTide Therapeutics Inc (2511.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 62.60, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.73.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3803.26 and a market capitalization of 2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

62.60RSI (14)
0.19MACD
26.94ADX
Stats data is not available for 2511.HKStats details for 2511.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 2511.HKAnalyst Recommendations details for 2511.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

HighTide Therapeutics, Inc., an investment holding company, engages in the discovery, research and development, and commercialization of multifunctional therapies for the treatment of metabolic and digestive diseases with unmet medical needs. Its lead product candidate is HTD1801, a gut-liver anti-inflammatory metabolic modulator that targets metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug for the treatment of alcoholic hepatitis; HTD1804 to treat obesity; HTD1805, a multifunctional small molecule drug for the treatment of metabolic diseases; and HTD2802 for the treatment of inflammatory bowel disease. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.

CEO

Liping Liu

Employees

70

Headquarters

18B-102, Zhonghaixin Innovation Industry City, Shenzhen

Founded

2023

Frequently Asked Questions

;